It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2017

Evotec Enters into Research Collaboration with CRTD to Discover Novel Therapies for Retinal Diseases
Nerina Coppini, 13 December 2017

COLLABORATION HIGHLIGHTS EVT INNOVATE’S BUSINESS MODEL TO ACCESS LEADING ACADEMIC EXPERTISE CRTD’S NEXT GENERATION STEM CELL MODELLING WILL ACCELERATE EVOTEC’S ABILITY TO DISCOVER NEW RETINAL DISEASE DRUGS Dresden and Hamburg, Germany, 13 December 2017:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that...

Evotec’s Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact
Nerina Coppini, 11 December 2017

THE £ 13 M DRUG DISCOVERY PARTNERSHIP BETWEEN OXFORD UNIVERSITY, OXFORD SCIENCES INNOVATION AND EVOTEC SUPPORTED 12 NEW PROJECTS IN FIRST YEAR OF OPERATION Hamburg, Germany, 11 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the £ 13 m drug discovery partnership between Oxford...

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim
Nerina Coppini, 1 December 2017

ACHIEVEMENT MARKS 24TH MILESTONE UNDER ALLIANCE TO DATE Hamburg, Germany, 01 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of € 2.00 m to Evotec. The milestone was for...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard